Alberto Carmona-Bayonas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3320257/publications.pdf

Version: 2024-02-01

107 1,693 papers citations

citations

346980

35 g-index

112 all docs 112 docs citations 112 times ranked

22

h-index

2368 citing authors

#	Article	IF	CITATIONS
1	External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study. Neuroendocrinology, 2022, 112, 88-100.	1.2	6
2	Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy. Oncologist, 2022, 27, e328-e339.	1.9	3
3	Anxiety and depression in patients with advanced cancer during the COVID-19 pandemic. Supportive Care in Cancer, 2022, 30, 3363-3370.	1.0	28
4	Bayesian interpretation of immunotherapy trials with dynamic treatment effects. European Journal of Cancer, 2022, 161, 79-89.	1.3	3
5	Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry. Biomedicines, 2022, 10, 148.	1.4	4
6	A prognostic model to identify short survival expectancy of medical oncology patients at the time of hospital discharge. ESMO Open, 2022, 7, 100384.	2.0	0
7	Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit. Cancer Investigation, 2022, 40, 184-188.	0.6	4
8	Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence. European Journal of Internal Medicine, 2022, 100, 33-45.	1.0	8
9	Medicine before and after David Cox. European Journal of Internal Medicine, 2022, 98, 1-3.	1.0	4
10	Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial. Thrombosis and Haemostasis, 2022, 122, 1653-1661.	1.8	1
11	Resilience, Social Support, and Anxious Preoccupation in Patients with Advanced Cancer during COVID-19 Pandemic. Cancer Investigation, 2022, , 1-8.	0.6	1
12	Prediction of the generalization of myasthenia gravis with purely ocular symptoms at onset: a multivariable model development and validation. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642211045.	1.5	2
13	Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. ESMO Open, 2022, 7, 100514.	2.0	2
14	Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients. Cancers, 2022, 14, 3106.	1.7	6
15	Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology). Clinical and Translational Oncology, 2021, 23, 799-811.	1.2	2
16	Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis. Clinical and Translational Oncology, 2021, 23, 657-662.	1.2	8
17	External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?. Gastric Cancer, 2021, 24, 445-456.	2.7	7
18	External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	1.4	5

#	Article	IF	Citations
19	Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Pancreatology, 2021, 21, 215-223.	0.5	2
20	Impact of Obesity on Quality of Life, Psychological Distress, and Coping on Patients with Colon Cancer. Oncologist, 2021, 26, e874-e882.	1.9	8
21	Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer, 2021, 24, 926-936.	2.7	8
22	Social support, coping strategies and sociodemographic factors in women with breast cancer. Clinical and Translational Oncology, 2021, 23, 1955-1960.	1.2	22
23	Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells. Biomedicines, 2021, 9, 523.	1.4	6
24	Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clinical and Translational Oncology, 2021, 23, 2046-2056.	1.2	0
25	Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. Scientific Reports, 2021, 11, 14321.	1.6	8
26	Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy. Npj Breast Cancer, 2021, 7, 92.	2.3	8
27	Prospective Study Comparing Clinicians' and Cancer Patients' Estimates of Risk of Relapse and Toxicity with Adjuvant Chemotherapy. Cancer Investigation, 2021, 39, 589-596.	0.6	3
28	Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. Cancers, 2021, 13, 4514.	1.7	6
29	Olaratumab-induced Biomarker Modulation in Sarcomasâ€"Letter. Molecular Cancer Therapeutics, 2021, 20, 2093-2093.	1.9	0
30	Causal considerations can inform the interpretation of surprising associations in medical registries. Cancer Investigation, 2021, , 1-27.	0.6	11
31	Learning in times of stress: Lessons from COVID-19 that will last throughout this century. European Journal of Internal Medicine, 2021, , .	1.0	1
32	Coping strategies and depressive symptoms in cancer patients. Clinical and Translational Oncology, 2020, 22, 330-336.	1.2	25
33	Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. Clinical and Translational Oncology, 2020, 22, 734-750.	1.2	8
34	TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM). Clinical and Translational Oncology, 2020, 22, 1423-1424.	1.2	0
35	Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings. European Journal of Cancer, 2020, 136, 159-168.	1.3	13
36	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. PLoS ONE, 2020, 15, e0235848.	1.1	14

#	Article	IF	CITATIONS
37	A snapshot of cancer-associated thromboembolic disease in 2018–2019: First data from the TESEO prospective registry. European Journal of Internal Medicine, 2020, 78, 41-49.	1.0	22
38	Does active smoking worsen Covid-19?. European Journal of Internal Medicine, 2020, 77, 129-131.	1.0	8
39	SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clinical and Translational Oncology, 2020, 22, 236-244.	1.2	28
40	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
41	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		O
42	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
43	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		O
44	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. Journal of Clinical Oncology, 2019, 37, 2571-2580.	0.8	49
45	Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer. Thrombosis and Haemostasis, 2019, 119, 1849-1859.	1.8	24
46	Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). British Journal of Cancer, 2019, 121, 537-544.	2.9	18
47	Quality of life, coping, and psychological and physical symptoms after surgery for non-metastatic digestive tract cancer. Surgical Oncology, 2019, 31, 26-32.	0.8	16
48	Incidence of sleep problems and their mediating role on depression and anxious preoccupation in patients with resected, non-advanced cancer: data from NEOcoping study. Clinical and Translational Oncology, 2019, 21, 1104-1107.	1.2	4
49	Effects of pessimism, depression, fatigue, and pain on functional health-related quality of life in patients with resected non-advanced breast cancer. Breast, 2019, 44, 108-112.	0.9	36
50	Differences in coping strategies among young adults and the elderly with cancer. Psychogeriatrics, 2019, 19, 426-434.	0.6	29
51	Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. Clinical and Translational Oncology, 2019, 21, 1781-1785.	1.2	9
52	Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. Oncologist, 2019, 24, e687-e695.	1.9	19
53	Biopsychosocial and clinical characteristics in patients with resected breast and colon cancer at the beginning and end of adjuvant treatment. BMC Cancer, 2019, 19, 1143.	1.1	21
54	Common misconceptions in the prognostic evaluation of clinically stable patients with febrile neutropenia and solid tumors. Clinical and Translational Oncology, 2019, 21, 1112-1114.	1.2	0

#	Article	IF	CITATIONS
55	SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Clinical and Translational Oncology, 2019, 21, 75-86.	1.2	21
56	Risk of malnutrition and emotional distress as factors affecting health-related quality of life in patients with resected cancer. Clinical and Translational Oncology, 2019, 21, 687-691.	1.2	13
57	The mediating role of spirituality (meaning, peace, faith) between psychological distress and mental adjustment in cancer patients. Supportive Care in Cancer, 2018, 26, 1411-1418.	1.0	32
58	The relationship between physician and cancer patient when initiating adjuvant treatment and its association with sociodemographic and clinical variables. Clinical and Translational Oncology, 2018, 20, 1392-1399.	1,2	10
59	Factors associated with anxiety and depression in cancer patients prior to initiating adjuvant therapy. Clinical and Translational Oncology, 2018, 20, 1408-1415.	1.2	42
60	Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist, 2018, 23, 422-432.	1.9	66
61	Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. European Journal of Surgical Oncology, 2018, 44, 1191-1198.	0.5	42
62	Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC. Medicina Intensiva, 2018, 42, 363-369.	0.4	24
63	Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric Cancer, 2018, 21, 96-105.	2.7	16
64	Key points to optimizing management and research on cancer-associated thrombosis. Clinical and Translational Oncology, 2018, 20, 119-126.	1.2	2
65	The prognostic impact of additional intrathoracic findings in patients with cancer-related pulmonary embolism. Clinical and Translational Oncology, 2018, 20, 230-242.	1.2	4
66	Top ten errors of statistical analysis in observational studies for cancer research. Clinical and Translational Oncology, 2018, 20, 954-965.	1.2	17
67	Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis. Journal of Geriatric Oncology, 2018, 9, 254-264.	0.5	14
68	CISNE or MASCC, which predictor is really the weakest in febrile neutropenia?. European Journal of Internal Medicine, 2018, 50, e33-e34.	1.0	3
69	Complexity and uncertainty in the critical care of cancer patients in the era of immunotherapy and targeted therapies. Medicina Intensiva, 2018, 42, 570-571.	0.4	5
70	Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC. Medicina Intensiva (English Edition), 2018, 42, 363-369.	0.1	0
71	Psychometric properties of the Shared Decision-Making Questionnaire (SDM-Q-9) in oncology practice. International Journal of Clinical and Health Psychology, 2018, 18, 143-151.	2.7	31
72	Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. Oncotarget, 2018, 9, 36894-36905.	0.8	9

#	Article	IF	CITATIONS
73	Tapentadol for Cancer Pain Management: A Narrative Review. Pain Practice, 2017, 17, 1075-1088.	0.9	14
74	Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. British Journal of Cancer, 2017, 116, 994-1001.	2.9	40
75	FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. Clinical and Translational Oncology, 2017, 19, 997-1009.	1.2	11
76	Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. British Journal of Cancer, 2017, 116, 1526-1535.	2.9	46
77	Validation of SDM-Q-Doc Questionnaire to measure shared decision-making physician's perspective in oncology practice. Clinical and Translational Oncology, 2017, 19, 1312-1319.	1.2	21
78	Supportive care in pancreatic ductal adenocarcinoma. Clinical and Translational Oncology, 2017, 19, 1293-1302.	1,2	26
79	Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients. Journal of the National Cancer Institute, 2017, 109, djw265.	3.0	9
80	The time has come for new models in febrile neutropenia: a practical demonstration of the inadequacy of the MASCC score. Clinical and Translational Oncology, 2017, 19, 1084-1090.	1.2	13
81	Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. European Respiratory Journal, 2017, 49, 1600282.	3.1	52
82	Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study. European Journal of Radiology, 2017, 87, 66-75.	1,2	9
83	Hyperreligiosity in malignant brain tumors: a case report and accompanying bibliographic review. Neurocase, 2017, 23, 88-95.	0.2	2
84	Prognostic Assessment of Febrile Neutropenia in the Emergency Department. Annals of Emergency Medicine, 2017, 70, 753-754.	0.3	О
85	Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. British Journal of Cancer, 2017, 117, 775-782.	2.9	77
86	Capecitabine and temozolomide in grade $1/2$ neuroendocrine tumors: a Spanish multicenter experience. Future Oncology, 2017, 13, 615-624.	1.1	32
87	Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors. Clinical and Translational Oncology, 2017, 19, 386-395.	1.2	6
88	Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. Gastric Cancer, 2017, 20, 465-474.	2.7	20
89	Chronic opioid therapy in long-term cancer survivors. Clinical and Translational Oncology, 2017, 19, 236-250.	1.2	48
90	Psychometric properties of Liverpool Stoicism Scale (LSS) in a cohort of patients with resected cancer in adjuvant treatment. Anales De Psicologia, 2017, 33, 621.	0.3	5

#	Article	IF	CITATIONS
91	On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1379-1388.	2.3	19
92	A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. British Journal of Cancer, 2016, 114, 1191-1198.	2.9	14
93	On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism. Thrombosis Research, 2016, 143, 76-85.	0.8	17
94	Valor pronÃ ³ stico de la tomografÃa computarizada en la tromboembolia pulmonar aguda. Radiologia, 2016, 58, 391-403.	0.3	5
95	Management of infection and febrile neutropenia in patients with solid cancer. Clinical and Translational Oncology, 2016, 18, 557-570.	1.2	14
96	Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer and Metastasis Reviews, 2015, 34, 823-842.	2.7	39
97	Prediction of Serious Complications in Patients With Seemingly Stable Febrile Neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a Prospective Cohort of Patients From the FINITE Study. Journal of Clinical Oncology, 2015, 33, 465-471.	0.8	118
98	Should Anticoagulation Therapy Be Withheld in Patients With Active Cancer After 6 Months of Low–Molecular Weight Heparin?. Journal of Clinical Oncology, 2015, 33, 1713-1713.	0.8	1
99	Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer and Metastasis Reviews, 2015, 34, 381-400.	2.7	49
100	Outpatient Management of Cancer-Related Pulmonary Embolism: a Propensity Score-Matched Analysis of 803 Patients from the Epiphany Study. Annals of Oncology, 2014, 25, iv519.	0.6	1
101	Outpatient Management of Pulmonary Embolism in Cancer: Data on a Prospective Cohort of 138 Consecutive Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 365-373.	2.3	38
102	Bacteremia in adult cancer patients with apparently stable febrile neutropenia: data from a cohort of 692 consecutive episodes from a single institution. Journal of Community and Supportive Oncology, 2014, 12, 312-320.	0.1	4
103	Stress-induced hyperglycemia is a valuable biomarker in febrile neutropenia. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 12-14.	0.7	3
104	Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. British Journal of Cancer, 2011, 105, 612-617.	2.9	64
105	Acute Inflammation and Micrometastasis Proliferation: A Fissure in the Uniformitarian Façade of Cancer. Japanese Journal of Clinical Oncology, 2009, 39, 192-194.	0.6	2
106	Surgery and stem cell niches: An Achilles' heel of metastatic cancer. Bioscience Hypotheses, 2009, 2, 345-349.	0.2	0
107	Tailored hormonal therapy in secretory adrenocortical cancer. Annals of Oncology, 2007, 18, 1281.	0.6	O